A federal judge blocked parts of the Trump administration’s HHS reorganization plan, ruling sweeping layoffs likely illegal, and temporarily halting implementation. Approximately 20,000 HHS jobs were cut, with impacts across FDA, CDC, and NIH, causing regulatory delays. Meanwhile, bluebird bio went private under private equity ownership amid market struggles, signaling a shift in pharma investment dynamics. Additionally, Nordic Capital acquired Arcadia to expand data-driven value-based care solutions.